Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Q2 2026 Earnings Presentation
34 slides from Innate Pharma Sa Class A's earnings presentation, August 2026
Slide 1: Company overview
Company overview August 2026
Slide 2: Disclaimer on forward-looking information and risk factors
Disclaimer on forward-looking information and risk factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains certai
Slide 3: A focused oncology company built for impact
A focused oncology company built for impact High-conviction targets In-house expertise and technologies to discover differentiated Ab therapeutics INNATE PHARMA Clinical & commercial value Smart & agile execution Focused on 3 high-value clinical assets Reshaped and fit-for-purpose Short-term catalys
Slide 4: A late-stage partnered portfolio and a proprietary ADC pipeline
A late-stage partnered portfolio and a proprietary ADC pipeline LATE-STAGE PARTNERED ASSETS PROPRIETARY ADC PIPELINE Towards Phase 3 initiation in H2 2026* Phase 3 readout in H2 2026 Phase 1 data in H2 2026 LACUTAMAB MONALIZUMAB IPH4502 Anti-KIR3DL2 mAb in CTCL Anti-NKG2A mAb in NSCLC Nectin-4 ADC i
Slide 5: Strategic partnership with Sobi to license lacutamab in T-cell lymphoma
Lacutamab Strategic partnership with Sobi to license lacutamab in T-cell lymphoma* To enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL Partnership o
Slide 6: Lacutamab, anti-KIR3DL2 mAb
Lacutamab, anti-KIR3DL2 mAb Partnered with Sobi* Progressing towards Phase 3 in CTCL** Lacutamab is an investigational antibody under clinical evaluation. It is not approved for any indication, and its safety and efficacy have not been established. *Closing of the transaction is subject to closing c
Slide 7: Lacutamab is a cytotoxic antibody targeting KIR3DL2 expressed on tumors
Lacutamab Lacutamab is a cytotoxic antibody targeting KIR3DL2 expressed on tumors Precise targeting of tumor-specific antigen leads to deep tumor cell depletion KIR3DL2 is a tumor-associated antigen expressed in CTCL and PTCL Lacutamab is an investigational antibody under clinical evaluation. It is
Slide 8: KIR3DL2 represents a high-conviction target in CTCL and PTCL with high unmet medical need
Lacutamab KIR3DL2 represents a high-conviction target in CTCL and PTCL with high unmet medical need Sézary syndrome Mycosis fungoides Peripheral T-cell lymphoma (SS) (MF) (PTCL) ~5% of CTCL ~70% of CTCL ~10% of NHL Epidemiology in US ~300 patients incidence ~3,000 patients incidence ~7,000 patients
Slide 9: CTCL patients face a high unmet medical need
Lacutamab CTCL patients face a high unmet medical need Poor outcomes in advanced stages Strong impact on quality of life 94% 84% 78% Pruritus (itching) 5Y-OS (%) 47% 47% Visible disfiguring skin 40% 37% changes 18% 18% Fatigue and sleep disturbance IA IB IIA IIB IIIA IIIB IVA1 IVA2 IVB MF Early-stag
Slide 10: In Phase 2 TELLOMAK, lacutamab demonstrated clinical benefit in SS patients
Lacutamab In Phase 2 TELLOMAK, lacutamab demonstrated clinical benefit in SS patients with ≥2 prior lines of systemic therapy including mogamulizumab TELLOMAK Phase 2 - Cohort 1 (N=63 patients) : SS patients post-mogamulizumab ≥2 prior lines of systemic therapy Global ORR 42.9% (95% CI [31.4-55.1])
Slide 11: In mycosis fungoides, lacutamab induced deep responses regardless of KIR3DL2 expression level
Lacutamab In mycosis fungoides, lacutamab induced deep responses regardless of KIR3DL2 expression level TELLOMAK Phase 2 – MF Cohorts KIR3DL2 ≥ 1% or KIR3DL2 <1% (N=107 patients), ≥2 prior lines of systemic therapy Global ORR 19.6% (95% CI [13.2-28.1]) Median DoR 13.8 months (95% CI [7.4-NE]) Median
Slide 12: Lacutamab is progressing towards Phase 3 initiation and a potential Accelerated Approval in Sézary syndrome
Lacutamab Lacutamab is progressing towards Phase 3 initiation and a potential Accelerated Approval in Sézary syndrome Breakthrough Path to FDA clearance to Therapy Accelerated proceed with Designation for R/R SS Approval in SS Phase 3 Feb 2025 Nov 2025 Fast Track designation (FDA) Phase 2 TELLOMAK d
Slide 13: TELLOMAK-3, a confirmatory Phase 3 trial in CTCL
Lacutamab TELLOMAK-3, a confirmatory Phase 3 trial in CTCL Open-label, multi-center, randomized comparative Phase 3 study of lacutamab in R/R patients with MF or SS Primary Key secondary endpoint endpoints Lacutamab KEY ELIGIBILITY SS cohort Randomization PFS CRITERIA Post moga OS 1:1 (BICR) n=108 R
Slide 14: Target positioning for lacutamab in future NCCN Guidelines
Lacutamab Target positioning for lacutamab in future NCCN Guidelines Stage IA Stage IB IIA Stage IIB Stage III Stage IV Skin Directed Topical corticosteroids, imiquimod, retinoids, phototherapy (NB-UVB or PUVA), localized radiation therapy, total-skin electron beam therapy Bexarotene Interferon-alfa
Slide 15: Current CTCL market is fragmented and needs new effective therapies
Lacutamab Current CTCL market is fragmented and needs new effective therapies Mogamulizumab is approved for adult patients with relapsed or refractory MF or SS following at least 1 prior systemic therapy Sézary syndrome Mycosis fungoides Methotrexate Clinical trial 2% 2% 1% 2% Adcetris 3% 3% 6% 10%
Slide 16: A significant untapped growth opportunity for lacutamab in CTCL
Lacutamab A significant untapped growth opportunity for lacutamab in CTCL Large CTCL Mogamulizumab sales validate Lacutamab positioned to Patient Population CTCL commercial potential expand the CTCL market US patients1 prevalence Capture the post-Moga SS market Sézary Mycosis syndrome fungoides FDA-
Slide 17: Lacutamab market potential in CTCL is >$500M
Lacutamab Lacutamab market potential in CTCL is >$500M Up to $150M* Up to $500M* >$500M* Patient Incidence # Expand use of CTCL systemic therapy for market 1L Systemic therapy early-stage and expansion other CTCL patients Mycosis Mycosis 2L fungoides fungoides Sézary Sézary Sézary 3L+ syndrome syndr
Slide 18: Lacutamab positioned for clinical impact and commercial value in CTCL
Lacutamab Lacutamab positioned for clinical impact and commercial value in CTCL Strong Phase 2 data addressing a Compelling Regulatory Path to value high unmet commercial profile momentum medical need Durable anti-tumor activity Peak year sales potential Potential AA pathway with a favorable tolerab
Slide 19: IPH4502 Novel and differentiated DAR8 Nectin-4 exatecan ADC
IPH4502 Novel and differentiated DAR8 Nectin-4 exatecan ADC IPH4502 is an investigational antibody under clinical evaluation. It is not approved for any indication, and its safety and efficacy have not been established. 19
Slide 20: IPH4502: Nectin-4 expression in solid tumors
IPH4502 Nectin-4 expression in solid tumors 100 No Nectin-4 drug approved PADCEV (EV) is approved solely for patients with 01 urothelial cancer, where expression of Nectin-4 is % of Nectin-4 expressing 80 the highest tumor samples 60 PADCEV induced toxicity frequently leads to 02 discontinuation of
Slide 21: IPH4502: novel and differentiated DAR8 Nectin-4 exatecan ADC
IPH4502 IPH4502: novel and differentiated DAR8 Nectin-4 exatecan ADC Target profile Binder Linker Payload Proprietary humanized anti-Nectin-4 antibody Cleavable Exatecan, a topoisomerase I inhibitor • High affinity • Hydrophilic → improved half-life, low clearance • Active in EV/MMAE-resistant model
Slide 22: Preclinical activity supports IPH4502 opportunity in bladder cancer and across solid tumors
IPH4502 Preclinical activity supports IPH4502 opportunity in bladder cancer and across solid tumors IPH4502 activity in Post-EV setting IPH4502 activity in solid tumors PDX models of acquired EV resistance (bladder cancer) PDX models with low and heterogeneous Nectin-4 expression HNSCC TNBC EsoC PDX
Slide 23: A First-in-Human Phase 1 clinical trial evaluating IPH4502 in solid tumors
IPH4502 A First-in-Human Phase 1 clinical trial evaluating IPH4502 in solid tumors A Phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors (NCT06781983) STUDY Dose escalation (N=76 patients) Dose optimization OBJECTIVE
Slide 24: IPH4502, a differentiated Topo I Nectin-4 ADC beyond MMAE limitations
IPH4502 IPH4502, a differentiated Topo I Nectin-4 ADC beyond MMAE limitations US/ Global China IPH4502 differentiated Nectin-4 ADC design IPH4502 • Exatecan payload to overcome key MMAE-related limitations; Innate no CYP2D6 genotyping requirement (unlike LY4052031) Pharma • Proprietary stable linker
Slide 25: IPH4502: Positioned to address the treatment gap in la/m UC post-EV
IPH4502 IPH4502: Positioned to address the treatment gap in la/m UC post-EV Most patients progress No established 2L within 2y after EV+P1 standard after EV+P2 IPH4502 EV-302 trial EV-302 follow-up Preliminary anti- Subsequent treatment pathways after progression on EV+P tumor activity observed in U
Slide 26: Preclinical ADCs
Preclinical ADCs Next-generation ADCs to overcome current ADC limitations 26
Slide 27: A preclinical portfolio of differentiated ADC drug candidates
A preclinical portfolio of differentiated ADC drug candidates Built on IPH proprietary linker, at clinical stage via IPH4502 IPH ADC platform designed to overcome current ADC limitations Objective Expand indications by overcoming Unlock activity in Overcome TAg heterogeneity low-expressing tumors pa
Slide 28: Monalizumab: Co-developed with AstraZeneca, Phase 3 PACIFIC-9 trial ongoing in NSCLC
Monalizumab Co-developed with AstraZeneca, Phase 3 PACIFIC-9 trial ongoing in NSCLC Monalizumab is an investigational antibody under clinical evaluation. It is not approved for any indication, and its safety and efficacy have not been established. NSCLC: Non-Small Cell Lung Cancer 28
Slide 29: Monalizumab and durvalumab act synergistically to block the inhibitory action of tumor cells
monalizumab Monalizumab and durvalumab act synergistically to block the inhibitory action of tumor cells on tumor-infiltrating NK and CD8 T cells COAST, a global, open-label, Phase 2 study of durvalumab (D) alone or combined with the anti-CD73 monoclonal antibody (mAb) oleclumab (O) or anti-NKG2A mA
Slide 30: PACIFIC-9: Phase 3 trial of durvalumab + oleclumab or monalizumab in unresectable stage III NSCLC
monalizumab PACIFIC-9: Phase 3 trial of durvalumab + oleclumab or monalizumab in unresectable stage III NSCLC ✓ Three Phase 2 trials supporting rationale of combination in early NSCLC (COAST, NeoCOAST, NeoCOAST-2) N=1051 Phase 3 PACIFIC-9 data expected in H2 2026 Barlesi et al. Future Oncol. 2024; c
Slide 31: Financial highlights of the partnership with AstraZeneca on monalizumab
monalizumab Financial highlights of the partnership with AstraZeneca on monalizumab Amounts received Total amount of the agreement: $1.275B Potential milestones still to receive Milestone Initial payments 250 100 payments Development and regulatory 50 50 400 In US$ million Commercialization 425 Roya
Slide 32: Conclusion
Conclusion Upcoming catalysts All milestones, projected sales, and timelines are based on management’s current expectations and subject to change 32
Slide 33: A focused portfolio of 3 high-value assets driving Innate's value creation
A focused portfolio of 3 high-value assets driving Innate’s value creation LACUTAMAB MONALIZUMAB IPH4502 Anti-KIR3DL2 mAb in CTCL Anti-NKG2A mAb in NSCLC Nectin-4 ADC in solid tumors TOWARDS PHASE 3 | TELLOMAK -3 PHASE 3 | PACIFIC -9 PHASE 1 | DOSE ESCAL ATION Wholly owned by Innate Pharma UPCOMING
Slide 34: Thank you
EURONEXT : IPH.PA NASDAQ : IPHA Thank you www.innate-pharma.com investors@innate-pharma.fr 34